

Christoph Springfield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9021029/publications.pdf>

Version: 2024-02-01

59
papers

2,285
citations

361413
20
h-index

223800
46
g-index

61
all docs

61
docs citations

61
times ranked

3884
citing authors

#	ARTICLE	IF	CITATIONS
1	Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 275, 962-971.	4.2	57
2	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3163-3174.	2.5	3
3	Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2022, 11, 2027148.	4.6	11
4	Intraepithelial TIRC7+ immune cells are positive prognosticators in cholangiocarcinoma and represent a potential target for immunotherapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
5	OUP accepted manuscript. <i>British Journal of Surgery</i> , 2022, , .	0.3	3
6	The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 285-286.	27.6	15
7	Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer â€” The PICCASSO phase I trial. <i>European Journal of Cancer</i> , 2022, 167, 112-122.	2.8	35
8	Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i>-fp) solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3099-3099.	1.6	16
9	FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2â€”Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 3750-3761.	1.6	28
10	CEND-1: a game changer for pancreatic cancer chemotherapy?. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 900-902.	8.1	6
11	Poly(<sc>ADP</sc>-ribose) polymerase inhibition in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 373-384.	2.8	11
12	Peripheral blood and tissue assessment highlights differential tumor-circulatory gradients of IL2 and MIF with prognostic significance in resectable pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2021, 10, 1962135.	4.6	8
13	The Evolution of Adjuvant Trials in Pancreatic Cancer. , 2021, , 743-761.		1
14	Metastatic Acinar Cell Carcinoma of the Pancreas. <i>Pancreas</i> , 2021, 50, 300-305.	1.1	8
15	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 676-686.	3.0	20
16	Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5546-5556.	7.0	22
17	Perioperative immunotherapy for pancreatic cancer is on its way. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 534-537.	1.5	2
18	Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1333-1351.	7.3	16

#	ARTICLE	IF	CITATIONS
19	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. <i>BMC Cancer</i> , 2021, 21, 1079.	2.6	14
20	Clinical Impact of Molecular Subtyping of Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743908.	3.7	29
21	A Review of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2436.	7.4	10
22	Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. <i>Hpb</i> , 2020, 22, 224-232.	0.3	47
23	HER2 gene (ERBB2) Amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 871-880.	2.8	12
24	Successful BRAF/MEK inhibition in a patient with <i>BRAF</i> ^{V600E} -mutated extrapancreatic acinar cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005553.	1.2	13
25	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1033-1050.	2.5	14
26	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. <i>Pancreatology</i> , 2020, 20, 425-432.	1.1	11
27	Sequencing of serially passaged measles virus affirms its genomic stability and reveals a nonrandom distribution of consensus mutations. <i>Journal of General Virology</i> , 2020, 101, 399-409.	2.9	6
28	Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients. <i>Insights Into Imaging</i> , 2020, 11, 106.	3.4	11
29	Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3010-3010.	1.6	22
30	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	2.4	15
31	Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2761-2769.	2.5	7
32	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.	3.7	32
33	Chemotherapy for pancreatic cancer. <i>Presse Medicale</i> , 2019, 48, e159-e174.	1.9	171
34	Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. <i>Scientific Reports</i> , 2019, 9, 4338.	3.3	10
35	Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. <i>BMJ Open</i> , 2019, 9, e028696.	1.9	3
36	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. <i>BMC Cancer</i> , 2019, 19, 72.	2.6	32

#	ARTICLE	IF	CITATIONS
37	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 109-114.	6.4	71
38	Prognostic significance of microsatellite instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2019, 144, 1697-1703.	5.1	51
39	Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. <i>Cancer Imaging</i> , 2018, 18, 9.	2.8	23
40	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. <i>Clinical Cancer Research</i> , 2018, 24, 351-359.	7.0	81
41	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. <i>Cancer Discovery</i> , 2018, 8, 1087-1095.	9.4	189
42	Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression. <i>Gastrointestinal Tumors</i> , 2018, 5, 38-46.	0.7	8
43	Prostatic metastasis from intrahepatic cholangiocarcinoma. <i>Urology Case Reports</i> , 2018, 20, 90-91.	0.3	4
44	Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites. <i>Molecular Therapy - Oncolytics</i> , 2018, 9, 30-40.	4.4	27
45	An undifferentiated carcinoma at Klatskin-position with long-term complete remission after chemotherapy. <i>Oncotarget</i> , 2018, 9, 22230-22235.	1.8	2
46	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. <i>Pancreatology</i> , 2017, 17, 629-634.	1.1	16
47	Virotherapy Research in Germany: From Engineering to Translation. <i>Human Gene Therapy</i> , 2017, 28, 800-819.	2.7	19
48	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001974.	1.2	54
49	Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. <i>BMC Gastroenterology</i> , 2017, 17, 143.	2.0	17
50	A Tupaia paramyxovirus vector system for targeting and transgene expression. <i>Journal of General Virology</i> , 2017, 98, 2248-2257.	2.9	6
51	Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. <i>Oncotarget</i> , 2017, 8, 59991-59998.	1.8	15
52	Locally Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2016, 264, 457-463.	4.2	399
53	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <i>Cancer Cell</i> , 2016, 29, 587-601.	16.8	375
54	Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. <i>Oncology Research and Treatment</i> , 2015, 38, 596-603.	1.2	20

#	ARTICLE	IF	CITATIONS
55	Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 905-914.	1.5	14
56	Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 149.	1.9	3
57	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (>=70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg. <i>Pancreatology</i> , 2014, 14, 211-215.	1.1	25
58	Envelope-chimeric Entry-targeted Measles Virus Escapes Neutralization and Achieves Oncolysis. <i>Molecular Therapy</i> , 2011, 19, 1813-1820.	8.2	58
59	Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine. <i>Cancer Research</i> , 2007, 67, 10939-10947.	0.9	86